Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2017

View Archived Issues

FDA confirms regulatory pathway to approval for bempedoic acid/ezetimibe

Phase II trial reveals efficacy of tadekinig alfa in some patients with adult onset Still's disease

Semnur successfully completes phase I/II pharmacokinetic bridging trial of SP-102

Zynerba Pharmaceuticals begins phase I program for ZYN-001

AZD-4785 demonstrates safety and efficacy in preclinical models of KRAS-driven cancer

Ra Pharmaceuticals reports initial data from study of RA-101495 in PNH

Kissei Pharmaceutical identifies NK1 receptor antagonists

Bavarian Nordic reports promising results from phase II study of MVA-BN RSV

Bristol-Myers Squibb presents formylpeptide receptor agonists

SP-1373 has beneficial effects on body and liver weight in obesity models

ST Pharm discloses tankyrase inhibitors

Luc Therapeutics presents NMDA receptor modulators

Chromocell reaches milestone in collaboration with Astellas

Phase I study of KL-1333 begins

Phase II data for voxelotor in pediatric sickle cell disease patients presented

Launch of Inter-Institutional Glial Biology Initiative

Heptares collaborates with New York University on GPCR target implicated in glioblastoma

TrovaGene submits IND for phase Ib/II study of PCM-075

KaloBios Pharmaceuticals' IND for benznidazole in Chagas disease now active

Hanmi's HM-15211 demonstrates benefit in Parkinson's disease and NASH models

Eptinezumab meets primary and key secondary endpoints in phase III PROMISE 1 study

Marinus Pharmaceuticals announces ganaxolone clinical program in postpartum depression

NantCell enters agreement to acquire Altor BioScience

RaNA Therapeutics now Translate Bio

Mepolizumab begins phase III trial in severe bilateral nasal polyps

Sandoz's Erelzi approved in Europe

Eisai withdraws Halaven submission in China with plans to resubmit

Araclon receives Spanish clearance for phase II trials of ABvac40 in early Alzheimer's

Phase III ECHELON-1 trial of Adcetris meets primary endpoint

Maximum tolerated dose determined in phase I study of Wnt pathway inhibitor ETC-159

Sun Pharma and Indian NIV partner on Zika, Chikungunya and dengue

Phase II trial of topical TV-45070 in post-herpetic neuralgia misses endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...